<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="42255">(-)-Epigallocatechin</z:chebi> <z:chebi fb="0" ids="16918">gallate</z:chebi> (<z:chebi fb="0" ids="4806">EGCG</z:chebi>) is a potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> that is neuroprotective against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced brain damage </plain></SENT>
<SENT sid="1" pm="."><plain>However, the neuroprotective effects and possible mechanisms of action of <z:chebi fb="0" ids="4806">EGCG</z:chebi> after <z:mp ids='MP_0005039'>hypoxia</z:mp>-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (HI) have not been investigated </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we used a modified "Levine" model of HI to determine the effects of <z:chebi fb="0" ids="4806">EGCG</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Wistar rats were treated with either 0.9% saline or 50 mg/kg <z:chebi fb="0" ids="4806">EGCG</z:chebi> daily for 1 day and 1 h before HI induction and for a further 2 days post-HI </plain></SENT>
<SENT sid="4" pm="."><plain>At 26-days-old, both groups underwent permanent left common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> and exposure to 8% oxygen/92% nitrogen atmosphere for 1 h </plain></SENT>
<SENT sid="5" pm="."><plain>Histological assessment showed that <z:chebi fb="0" ids="4806">EGCG</z:chebi> significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (38.0+/-16.4 mm(3)) in comparison to HI + saline (99.6+/-15.6 mm(3)) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:chebi fb="0" ids="4806">EGCG</z:chebi> significantly reduced total (622.6+/-85.8 pmol L-[(3)H]<z:chebi fb="0" ids="18211">citrulline</z:chebi>/30 min/mg protein) and inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS) activity (143.2+/-77.3 pmol L-[(3)H]<z:chebi fb="0" ids="18211">citrulline</z:chebi>/30 min/mg protein) in comparison to HI+saline controls (996.6+/-113.6 and 329.7+/-59.6 pmol L-[(3)H]<z:chebi fb="0" ids="18211">citrulline</z:chebi>/30 min/mg protein for total NOS and iNOS activity, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Western blot analysis demonstrated that iNOS protein expression was also reduced </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, <z:chebi fb="0" ids="4806">EGCG</z:chebi> significantly increased endothelial and neuronal NOS protein expression compared with HI controls </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="4806">EGCG</z:chebi> also significantly preserved <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> energetics (complex I-V) and <z:chebi fb="2" ids="50744">citrate</z:chebi> synthase activity </plain></SENT>
<SENT sid="10" pm="."><plain>This study demonstrates that the neuroprotective effects of <z:chebi fb="0" ids="4806">EGCG</z:chebi> are, in part, due to modulation of NOS isoforms and preservation of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex activity and integrity </plain></SENT>
<SENT sid="11" pm="."><plain>We therefore conclude that the in vivo neuroprotective effects of <z:chebi fb="0" ids="4806">EGCG</z:chebi> are not exclusively due to its <z:chebi fb="11" ids="22586">antioxidant</z:chebi> effects but involve more complex signal transduction mechanisms </plain></SENT>
</text></document>